What happens when lower drug prices don’t make medicine more accessible for patients? Heart patients covered by Medicare Part D are about to find out.
Last year, manufacturers of cholesterol-busting PCSK9 inhibitors cut the drugs’ sticker price by 60%. But new research says that patients may still pay $100 or more a month for the medicine, which protects them from a heart attack or stroke.